Morgan Stanley’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Morgan Stanley’s Portfolio TMBR Stock Details TMBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8	Closed	-$14	–	8018
2022 Q4	$14	Buy	+8	New	+$19	﹤0.01%	7793
2022 Q3	–	Hold	0	–	–	–	8103
2022 Q2	–	Hold	0	–	–	–	8202
2022 Q1	–	Hold	0	–	–	–	8294
2021 Q4	–	Hold	0	–	–	–	8290
2021 Q3	–	Hold	0	–	–	–	8140
2021 Q2	–	Hold	0	–	–	–	7879
2021 Q1	–	Hold	0	–	–	–	7621
2020 Q4	–	Hold	0	–	–	–	7175
2020 Q3	–	Sell	-60	Closed	-$7K	–	6897
2020 Q2	$7K	Buy	+60	New	+$10.5K	﹤0.01%	6255
2020 Q1	–	Hold	0	–	–	–	6801
2019 Q4	–	Hold	0	–	–	–	6846
2019 Q3	–	Sell	-2	Closed	-$479	–	6842
2019 Q2	$1K	Buy	+2	New	+$1.56K	﹤0.01%	6594
2019 Q1	–	Hold	0	–	–	–	6774
2018 Q4	–	Hold	0	–	–	–	6802
2018 Q3	–	Hold	0	–	–	–	6862
2018 Q2	–	Hold	0	–	–	–	6791
2018 Q1	–	Hold	0	–	–	–	6753
2017 Q4	–	Hold	0	–	–	–	6704
2017 Q3	–	Hold	0	–	–	–	6657
2017 Q2	–	Hold	0	–	–	–	6686
2017 Q1	–	Hold	0	–	–	–	6643
2016 Q4	–	Hold	0	–	–	–	6594
2016 Q3	–	Hold	0	–	–	–	6592

Other funds holding TMBR

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley's TMBR Position: Q1 2023 in Review

Morgan Stanley sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q1 2023, closing a stake of 8 shares — an estimated $14 sold.

Morgan Stanley first reported a position in TMBR in Q2 2019 and held it in 3 quarters. The position peaked at $7K in Q2 2020. 13 funds tracked by Wall St. Rank hold TMBR as of Q1 2023.

Morgan Stanley reported no remaining Timber Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Morgan Stanley sold 8 Timber Pharmaceuticals, Inc. shares in Q1 2023, an estimated $14.
Morgan Stanley first reported a position in Timber Pharmaceuticals, Inc. in Q2 2019 and held it in 3 quarters.
Morgan Stanley's Timber Pharmaceuticals, Inc. position peaked at $7K in Q2 2020.
13 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.